Lixte Biotechnology Holdings, Inc. (LIXT)
Automate Your Wheel Strategy on LIXT
With Tiblio's Option Bot, you can configure your own wheel strategy including LIXT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LIXT
- Rev/Share 0.0
- Book/Share 0.2395
- PB 14.3657
- Debt/Equity 0.0
- CurrentRatio 1.8427
- ROIC -4.7248
- MktCap 15691078.0
- FreeCF/Share -0.9602
- PFCF -6.0068
- PE -3.0294
- Debt/Assets 0.0
- DivYield 0
- ROE -3.0856
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
24/7 Market News: LIXTE Showcases LB-100 at First Global Conference on Oncogenic Signaling Activation as Cancer Therapy
Published: August 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
LIXTE (NASDAQ: LIXT) publishes new data showing that its lead compound LB-100 can mediate activation of oncogenic signaling, which is toxic to cancer cells
Read More
24/7 Market News: LIXTE Biotechnology Spotlight- Revisiting the “Too Much of a Good Thing” Strategy for LB-100
Published: August 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
DENVER, Aug. 19, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com , a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, revisits the LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing novel cancer therapies by targeting the modulation of key cellular pathways, Nature Reviews Cancer editorial titled “Too Much of a Good Thing”, which explores a counterintuitive cancer therapy approach that underscores the growing promise of its lead compound, LB-100 Nature . The editorial underscores LIXTE's first-in-class PP2A inhibitor, LB-100, and its revolutionary potential to exploit oncogenic signaling for cancer …
Read More
LIXTE Biotechnology Holdings Provides Corporate Update
Published: August 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
-Completes Two Financings, Raising $6.5 Million- -Regains Compliance for Continued Listing on Nasdaq- -Announces Management Changes; Adds Two New Board Members- -Re-Establishes Scientific Advisory Committee- - Reports on New Findings Published in Scientific Journal Nature that Validate LIXTE's Ongoing Clinical Trials with LB-100- -Launches New Pre-Clinical Study- PASADENA, Calif, Aug. 18, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today provided an update on its recent activities. “This has been a transformative period for our company,” …
Read More
Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $5.0 Million Private Placement
Published: July 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
New York, NY, July 08, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the closing of a $5.0 million private placement for Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT), in which it served as the exclusive placement agent.
Read More
LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
PASADENA, CALIF., Feb. 11, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 434,784 shares of its common stock at a purchase price of $2.415 per share, in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to an aggregate of 434,784 shares of common stock. The warrants will have an exercise price of …
Read More
LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement
Published: February 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
PASADENA, CALIF., Feb. 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) ( Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that it has filed a request for withdrawal with the Securities and Exchange Commission (the “SEC”) of the Company's Registration Statement on Form S-1 (No. 333-282781), as amended, originally filed on October 23, 2024 (the “Registration Statement”), as the Company no longer intends to pursue a public offering under the Registration Statement at this time. The Registration Statement has not been declared effective by the SEC, and no securities have been …
Read More
About Lixte Biotechnology Holdings, Inc. (LIXT)
- IPO Date 2007-10-25
- Website https://lixte.com
- Industry Biotechnology
- CEO Bastiaan van der Baan
- Employees 2